BioMérieux's planned acquisition of Salt Lake City, Utah-based BioFire Diagnostics for $450 million plus undisclosed debt, announced earlier this week, will give the French clinical diagnostics firm a US-based "hub" for molecular diagnostics that it plans to not only keep intact but grow over the coming years, executives from both companies said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.